Northwest Biotherapeutics Disputes Patent Infringement Claims |
|
By: Northwest Biotherapeutics, Inc. Posted: 2007-08-01 09:53:24 |
|
Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS), announced today that Lonza Group AG has filed a complaint in the United States District Court for the District of Delaware against the company alleging infringement of certain patents involving gene expression technology. The company disputes the allegations in the complaint, denies the claims of infringement and particularly notes that its DCVax(R)-Brain product, which is moving toward early commercialization, does not now involve, and has never involved, any gene expression technology. The company intends to vigorously defend against the action.
About Northwest Biotherapeutics, Inc. Northwest Biotherapeutics, Inc. is a US-based biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two lead product candidates: 1. DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of Glioblastoma multiforme; and 2. DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent, non-metastatic prostate cancer. For further information, please visit the company web site at http://www.nwbio.com. Disclaimer Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the uncertainties of litigation in general and, specifically litigation involving intellectual property claims, including the lawsuit described herein. Additional information on these and other factors which could affect the company's results is included in its Securities and Exchange Commission ("SEC") filings and its filings pursuant to its listing on the Alternative Investment Market of the London Stock Exchange ("AIM"). Finally, there may be other factors not mentioned above or included in the company's SEC filings and/or AIM filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. |
| Trackback url: https://press.abc-directory.com/press/1821 |